Annual Report 2024 
Annual Report 2023 
Become an IRBLleida friend2024 Annual Report
Biomedical Research Institute of Lleida
2024 in numbers
Total staff
Researchers
Research groups
Principal investigators
New competitive projects
Scientific publications
Total IF
Medium IF
Scientific production Q1
New clinical studies
Fundraising (€)
Budget (€)
Contributions
Total collaborating companies
New collaborators
Contribution to IRBLleida
The contributions made by companies and organizations that work with IRBLleida have the mission of promoting, developing, managing and disseminating biomedical research in our region.
Donations allow us to investigate in our 5 research areas. IRBLleida has the support of 201 companies and organizations from Lleida.
Become a friend of the IRBLleida for the future of biomedical research in Lleida
To promote research on health and impact on the quality of life of the population.
To improve the treatment of many diseases, to the benefit of the health of our children, grandchildren and future generations.
To collaborate with the scientific community, with patients and citizens.
To promote Lleida and the region.
To share the values of the IRBLleida: responsibility, respect, rigour, generosity in synergy, inde-pendence of judgement, fairness in the distribution of resources, social commitment, leadership and enthusiasm.
Core facilities
The Technical Scientific Services (SCT) of the IRBLleida are facilities with infrastructures and large equipment necessary for the performance of specialised techniques.
Its mission is to provide scientific and technological support to IRBLleida's research groups, as well as external entities and companies, for the development of research and innovation projects in the field of biomedicine.
Biobank core
Microscopy and Cytometry core
Biostatistics core
Cell culture core
Animal housing facility
Clinical Research Support Unit (USIC)
Immunohistochemistry core
Lipidomics (PLICAT)
Respiratory medicine and chronic pathologies core
Proteomics and genomics core
Vascular image core - UDETMA
Centre for Applied Biomedical Experimental Research (CREBA)
Bioinformatics and Computational Biology (BIO2COMP)
Research areas
Research activity by areas and groups
Cancer
Chronic diseases, surgery and health care
Epidemiology, infectious diseases and public health
Neurosciences
Nutrition, metabolism and cellular stress
- Number of publications
- Total Impact Factor
Research activity
In 2024, IRBLleida researchers produced a total of 325 scientific publications, of which 292 are original publications, 27 are review articles and 6 are letters.
 Publications
|
 Average IF
|
 Cummulative IF
|
|
|---|---|---|---|
| Articles | 292 | 5,87 | 1.713 |
| Reviews | 27 | 7,33 | 198 |
| Letters | 6 | 4,32 | 26 |
| Total | 325 | 5,96 | 1.937 |
Publications according to typology
Scientific production in percentage of publications according to typology (article, review and letters).
Publications by Quartile
Scientific production for 2024 by specialty quartiles. Percentage of publications per quartile (Q).
Publications historical series
Total number of publications in the last 9 years.
Impact factor historical series
Evolution of the accumulated Impact Factor (IF) (bars) and average (blue line), The 2024 FI has been calculated according to the 2023 Journal Citation Report.
Funds from clinical trials and observational studies
Historical data on funds obtained from clinical trials and observational studies.
Communication
IRBLleida (general)
Chronic diseases, Surgery and Health Care Area
Nutrition, Metabolism and Cellular Stress Area
Cancer Area
Neurosciences Area
Epidemiology, Infectious Diseases and Public Health Area
Technical Scientific Services
- Media impacts (TV, radio, press and others) of the different scientific-technical groups and services in 2024.
Fundraising
Donations
| 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | |
|---|---|---|---|---|---|---|---|
| Number of companies and organizations | 157 | 166 | 135 | 157 | 179 | 193 | 201 |
Donations made by companies, organizations and IRBLleida friends since 2018.